| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#21 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_005 | hours:48 | treatment:CHX | concentration:20 µg/ml | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#21 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_005 | hours:48 | treatment:CHX | concentration:20 µg/ml | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#21 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_005 | hours:48 | treatment:CHX | concentration:20 µg/ml | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#22 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_006 | hours:48 | treatment:ETO | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#22 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_006 | hours:48 | treatment:ETO | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#22 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_006 | hours:48 | treatment:ETO | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#27 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_011 | hours:48 | treatment:I3M | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#27 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_011 | hours:48 | treatment:I3M | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#27 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_011 | hours:48 | treatment:I3M | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#26 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_010 | hours:48 | treatment:MC | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#26 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_010 | hours:48 | treatment:MC | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#26 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_010 | hours:48 | treatment:MC | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#25 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_009 | hours:48 | treatment:Serum | concentration:- | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#25 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_009 | hours:48 | treatment:Serum | concentration:- | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#25 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_009 | hours:48 | treatment:Serum | concentration:- | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#20 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_004 | hours:48 | treatment:STS | concentration:0.3 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#20 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_004 | hours:48 | treatment:STS | concentration:0.3 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#20 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_004 | hours:48 | treatment:STS | concentration:0.3 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#19 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_003 | hours:48 | treatment:TNFα | concentration:10 ng/ml | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#19 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_003 | hours:48 | treatment:TNFα | concentration:10 ng/ml | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#19 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_003 | hours:48 | treatment:TNFα | concentration:10 ng/ml | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#23 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_007 | hours:48 | treatment:TPG | concentration:2 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#23 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_007 | hours:48 | treatment:TPG | concentration:2 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#23 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_007 | hours:48 | treatment:TPG | concentration:2 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#24 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_008 | hours:48 | treatment:VAL | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#24 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_008 | hours:48 | treatment:VAL | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#24 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_008 | hours:48 | treatment:VAL | concentration:10 µM | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#18 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_002 | hours:48 | treatment:vehicle (DMSO) | concentration:- | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.13_2_#28 - VJ_17.05.13_Kinase_screeneing_48h_n1_FFA_012 | hours:48 | treatment:vehicle (DMSO) | concentration:- | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#18 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_002 | hours:48 | treatment:vehicle (DMSO) | concentration:- | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17_#28 - VJ_17.05.17_Kinase_screeneing_48h_n2_FFA_012 | hours:48 | treatment:vehicle (DMSO) | concentration:- | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#18 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_002 | hours:48 | treatment:vehicle (DMSO) | concentration:- | relative intensities |
| Reversed phase NEGATIVE ION MODE | VJ_17.05.17-n3_#28 - VJ_17.05.17_Kinase_screeneing_48h_n3_FFA_012 | hours:48 | treatment:vehicle (DMSO) | concentration:- | relative intensities |
Return to study ST001751 main page
Download data matrix(Free fatty acid analysis of NIH-3T3 cells treated with apoptotic inducers Reversed phase NEGATIVE ION MODE)
- Metabolomics Workbench
|